We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
Read MoreHide Full Article
Resmed (RMD - Free Report) has unveiled a comprehensive brand evolution to lead the global sleep and health technology revolution. The strategy unifies all Resmed brands under a single health technology brand, aiming to serve millions of consumers and healthcare professionals worldwide and reflect growing direct-to-consumer engagement.
The latest development follows the company’s 2014 brand update, which marked a shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy.
RMD Stock's Outlook Following the News
After the announcement yesterday, shares of Resmed dropped 4.6%, finishing at $225.79. On a promising note, the company has been a longstanding pioneer in respiratory therapy innovations, including continuous positive airway pressure (CPAP) therapy and digital health solutions. The latest development represents a pivotal step in its strategy to make sleep and breathing health a top priority in global healthcare. Hence, we expect the latest development to boost the market sentiment toward RMD stock.
Resmed presently boasts a market capitalization of $34.75 billion. The Zacks Consensus Estimate for the company’s 2025 earnings suggests a 22.7% increase. In the trailing four quarters, it delivered an earnings beat of 6.8%, on average.
More on Resmed’s Latest Rebranding
As part of the brand evolution, Resmed plans to consolidate its brands, products and services under a single Resmed identity over the next couple of years, creating a more streamlined view for both consumers and healthcare providers. The transformation also accompanies a new visual identity, redesigned logo and refreshed brand voice. Furthermore, the brand evolution coincides with Resmed’s three major market-facing initiatives aimed at reshaping perceptions of sleep therapy and expanding awareness of sleep apnea treatment.
Image Source: Zacks Investment Research
The company is set to launch its first U.S. consumer campaign aimed at destigmatizing CPAP therapy and positioning sleep health as more approachable. It will also introduce a targeted primary care physician (PCP) education campaign, starting in the United States, to help drive earlier diagnosis and intervention for sleep apnea and a sleep health awareness campaign in key markets across Asia Pacific and Europe focused on helping to overcome the barriers to seeking treatment for sleep apnea.
Industry Prospects Favoring RMD
Per a Research report, the global sleep apnea device market was valued at $4.5 billion in 2023 and is expected to witness a compound annual rate of 6.2% through 2030. The growing geriatric population's vulnerability to sleep apnea is expected to drive the adoption of sleep apnea devices. Furthermore, the entry of new players and an increased focus on innovative product development are driving market expansion, resulting in technologically advanced solutions.
Other Developments at Resmed
Last month, the company revealed the findings of its fifth annual Global Sleep Survey, with insights from respondents across 13 markets. The study underscored a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week. While awareness of sleep’s importance is growing, the research revealed that nearly one in four (22%) respondents choose to live with poor sleep rather than seek help.
RMD Stock Price Performance
In the past year, Resmed shares have rallied 17.3% compared with the industry’s rise of 8.9%.
Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 34.6% to 70 cents in the past 30 days. Shares of the company have surged 129.5% in the past year against the industry’s 14% fall. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Inspira shares have dipped 8.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 6.4% to $2.16 in the past 30 days. INSP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 332.5%. In the last reported quarter, it posted an earnings surprise of 55.4%.
Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 14.7% to $7.94 in the past 30 days. Shares of the company have jumped 11.8% in the past year against the industry’s 3.9% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
Resmed (RMD - Free Report) has unveiled a comprehensive brand evolution to lead the global sleep and health technology revolution. The strategy unifies all Resmed brands under a single health technology brand, aiming to serve millions of consumers and healthcare professionals worldwide and reflect growing direct-to-consumer engagement.
The latest development follows the company’s 2014 brand update, which marked a shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy.
RMD Stock's Outlook Following the News
After the announcement yesterday, shares of Resmed dropped 4.6%, finishing at $225.79. On a promising note, the company has been a longstanding pioneer in respiratory therapy innovations, including continuous positive airway pressure (CPAP) therapy and digital health solutions. The latest development represents a pivotal step in its strategy to make sleep and breathing health a top priority in global healthcare. Hence, we expect the latest development to boost the market sentiment toward RMD stock.
Resmed presently boasts a market capitalization of $34.75 billion. The Zacks Consensus Estimate for the company’s 2025 earnings suggests a 22.7% increase. In the trailing four quarters, it delivered an earnings beat of 6.8%, on average.
More on Resmed’s Latest Rebranding
As part of the brand evolution, Resmed plans to consolidate its brands, products and services under a single Resmed identity over the next couple of years, creating a more streamlined view for both consumers and healthcare providers. The transformation also accompanies a new visual identity, redesigned logo and refreshed brand voice. Furthermore, the brand evolution coincides with Resmed’s three major market-facing initiatives aimed at reshaping perceptions of sleep therapy and expanding awareness of sleep apnea treatment.
Image Source: Zacks Investment Research
The company is set to launch its first U.S. consumer campaign aimed at destigmatizing CPAP therapy and positioning sleep health as more approachable. It will also introduce a targeted primary care physician (PCP) education campaign, starting in the United States, to help drive earlier diagnosis and intervention for sleep apnea and a sleep health awareness campaign in key markets across Asia Pacific and Europe focused on helping to overcome the barriers to seeking treatment for sleep apnea.
Industry Prospects Favoring RMD
Per a Research report, the global sleep apnea device market was valued at $4.5 billion in 2023 and is expected to witness a compound annual rate of 6.2% through 2030. The growing geriatric population's vulnerability to sleep apnea is expected to drive the adoption of sleep apnea devices. Furthermore, the entry of new players and an increased focus on innovative product development are driving market expansion, resulting in technologically advanced solutions.
Other Developments at Resmed
Last month, the company revealed the findings of its fifth annual Global Sleep Survey, with insights from respondents across 13 markets. The study underscored a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week. While awareness of sleep’s importance is growing, the research revealed that nearly one in four (22%) respondents choose to live with poor sleep rather than seek help.
RMD Stock Price Performance
In the past year, Resmed shares have rallied 17.3% compared with the industry’s rise of 8.9%.
RMD’s Zacks Rank and Other Key Picks
Resmed currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space include Hims & Hers Health (HIMS - Free Report) , Inspira Medical Systems (INSP - Free Report) and Cardinal Health (CAH - Free Report) . Each of these carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 34.6% to 70 cents in the past 30 days. Shares of the company have surged 129.5% in the past year against the industry’s 14% fall. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Inspira shares have dipped 8.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 6.4% to $2.16 in the past 30 days. INSP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 332.5%. In the last reported quarter, it posted an earnings surprise of 55.4%.
Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 14.7% to $7.94 in the past 30 days. Shares of the company have jumped 11.8% in the past year against the industry’s 3.9% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise